Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  Y. Ko,et al.  Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study , 2017, Heart and Vessels.

[3]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[4]  H. Palevsky,et al.  Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. , 2016, Annals of the American Thoracic Society.

[5]  A. Sahebkar,et al.  The impact of statin therapy on plasma levels of von Willebrand factor antigen , 2015, Thrombosis and Haemostasis.

[6]  L. Howard,et al.  Pulmonary arterial hypertension: the burden of disease and impact on quality of life , 2015, European Respiratory Review.

[7]  J. Loyd,et al.  Toward Precision Medicine in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[8]  Maciej Banach,et al.  Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies , 2015, BMC Medicine.

[9]  A. Sahebkar,et al.  Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.

[10]  M. Banach,et al.  Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. , 2015, Atherosclerosis.

[11]  A. Sahebkar,et al.  A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations , 2015, Scientific Reports.

[12]  S. Matsuo,et al.  Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension. , 2015, The Journal of thoracic and cardiovascular surgery.

[13]  Orlando Santana,et al.  Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review. , 2015, Pulmonary pharmacology & therapeutics.

[14]  W. Aronow,et al.  Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension , 2014, Cardiology in review.

[15]  W. Aronow,et al.  Can echocardiographically estimated pulmonary arterial elastance be a non-invasive predictor of pulmonary vascular resistance? , 2014, Archives of medical science : AMS.

[16]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[17]  M. Gatzoulis,et al.  Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review. , 2014, International journal of cardiology.

[18]  R. Suda,et al.  Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[19]  Jeffrey N. Martin,et al.  Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection , 2014, AIDS.

[20]  S. A. Moosavi,et al.  Evaluation of the Effects of Atorvastatin on the Treatment of Secondary Pulmonary Hypertension due to Chronic Obstructive Pulmonary Diseases: A Randomized Controlled Trial , 2013, Iranian Red Crescent medical journal.

[21]  D. Welsh,et al.  Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. , 2012, American journal of respiratory cell and molecular biology.

[22]  O. Hilberg,et al.  Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease. , 2012, Respiratory medicine.

[23]  R. Moots,et al.  Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis , 2012, Rheumatology.

[24]  Lan Zhao,et al.  Atorvastatin in Pulmonary Arterial Hypertension (APATH) study , 2012, European Respiratory Journal.

[25]  S. Rich,et al.  Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[26]  R. Barr,et al.  Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT , 2011, Circulation.

[27]  Steven R. Jones,et al.  Statin Therapy is Associated with Decreased Pulmonary Vascular Pressures in Severe COPD , 2011, COPD.

[28]  R. Mohiaddin,et al.  Simvastatin as a treatment for pulmonary hypertension trial. , 2010, American journal of respiratory and critical care medicine.

[29]  J. Wharton,et al.  Simvastatin and sildenafil combine to attenuate pulmonary hypertension , 2009, European Respiratory Journal.

[30]  N. Chang,et al.  Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. , 2009, Clinical science.

[31]  V. Debari,et al.  Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study , 2008, International journal of clinical practice.

[32]  A. Lopes,et al.  Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. , 2008, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  D. Ku,et al.  Rosuvastatin Provides Pleiotropic Protection Against Pulmonary Hypertension, Right Ventricular Hypertrophy and Coronary Endothelial Dysfunction in Rats , 2008, American journal of physiology. Heart and circulatory physiology.

[34]  P. Vokonas,et al.  Statin use reduces decline in lung function: VA Normative Aging Study. , 2007, American journal of respiratory and critical care medicine.

[35]  S. Archer,et al.  Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[36]  R. Johns,et al.  Regression of chronic hypoxic pulmonary hypertension by simvastatin. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[37]  T. Murata,et al.  Statin Protects Endothelial Nitric Oxide Synthase Activity in Hypoxia-Induced Pulmonary Hypertension , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[38]  T. Shim,et al.  Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. , 2005, American journal of respiratory and critical care medicine.

[39]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[40]  P. Kao.  Simvastatin treatment of pulmonary hypertension: an observational case series. , 2005, Chest.

[41]  G. Berry,et al.  Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.

[42]  R. Johns,et al.  Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. , 2003, American journal of physiology. Heart and circulatory physiology.

[43]  F. Volkmar.  What is a "placebo controlled" study? , 2001, Journal of autism and developmental disorders.

[44]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[45]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[46]  Tony Travers,et al.  A Comprehensive Review , 1998 .

[47]  M. Pencina,et al.  Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. , 2016, Pharmacological research.

[48]  N. O'mara,et al.  Correction to Grade in: Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2016, Chest.

[49]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[50]  Le-Xin Wang,et al.  Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease , 2013 .

[51]  D. Sin,et al.  Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. , 2011, American journal of respiratory and critical care medicine.

[52]  D. Moher,et al.  Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke , 2010 .

[53]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[54]  A. Sung,et al.  Statins for Treatment of Pulmonary Hypertension , 2008 .

[55]  Bibliographic Sources,et al.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report , 2017 .